Sunday, October 11, 2026
ExploreSearch
Via News

Markets & Regulation

2 articles

U.S. Tax Rule Powers QQQI's Edge—Washington Could Pull It Without Warning

U.S. Tax Rule Powers QQQI's Edge—Washington Could Pull It Without Warning

QQQI's after-tax yield advantage rests entirely on a decades-old U.S. tax provision that regulators could revoke at any time. Risk analysts rate the consequences of reclassification as catastrophic, though the probability remains low. Global investors holding the fund carry an asymmetric exposure: stable gains today, sudden structural change possible tomorrow.

LM Salvado•
Lufax Drops 14%, Faces Class Action After PwC Quits Over Hidden Transactions

Lufax Drops 14%, Faces Class Action After PwC Quits Over Hidden Transactions

Chinese fintech Lufax lost 14% of its NYSE-listed stock value in January 2025 after PwC resigned, citing undisclosed related-party transactions for 2022–2023. A securities class action followed in April 2026, filed by Hagens Berman. The case is now a reference point for global investors assessing audit risk in cross-listed Chinese companies.

LM Salvado•
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Agentic AI Rewires Enterprise Software: Platform Incumbents, Governance, and a Funded Startup Wave
Enterprise software is being rebuilt around autonomous AI agents. Incumbents and large platforms (SAP with its Autonomous Suite and Joule, Zeta with AthenaOS/AIM/Athena MCP, Meta with its new Enterprise Platform) are racing to own the agent layer. Meanwhile, seed and Series A money flows to finance-office and vertical startups (Dextr, Latitude, Dentira, Light), and consolidation continues through acquisitions (Tiny–Oso Cloud, Harvey–Guardrails AI). Investor commentary stresses that AI is better at disrupting around the edges of systems of record than at replacing them, that it should not be trusted with finance calculations, and that governance must be enforced by the system rather than left to agents.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,369 source documents archived
Query this data → isubstrate.com